Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLEXI
NCT07489430Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in benign essential blepharospasm (BEB), sponsored by University of Pennsylvania. Started Sep 2026; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT07489430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489430.